ArticleCurrent medical science2025
PMEPA1-Mediated Treg Cell Impairment Promotes Endometrial Stromal Invasion via Excessive PI3K/AKT Signaling in Endometriosis.
Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MIS-C pathogenesis: immune dysregulation & viral triggers.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough immune dysregulation is implicated in the pathogenesis of endometriosis (EMs), the specific role of prostate transmembrane protein androgen induced 1 (PMEPA1) in modulating the function of regulatory T cells (Tregs) remains inadequately understood. This study aimed to elucidate the regulatory mechanisms by which PMEPA1 influences the activity of Tregs, thereby facilitating the invasion of endometrial stromal cells (ESCs).
methodsSingle-cell RNA sequencing (scRNA-seq) was performed on matched ectopic ovarian lesions and eutopic endometria from 3 patients. Clinical specimens from patients with EMs and control subjects were examined for PMEPA1 expression. Primary human Tregs isolated from peripheral blood mononuclear cells were subjected to PMEPA1 overexpression (via plasmid) or knockdown (via siRNA). Modulation of the PI3K pathway was conducted via the activator 740Y-P or the inhibitor LY294002. The secretion of IL-10 and TGF-β by Tregs was quantified using an enzyme-linked immunosorbent assay. Ectopic ESCs cocultured with modified Tregs were assessed for their proliferation, migration, and invasion capabilities.
resultsscRNA-seq data revealed significant upregulation of PMEPA1 in Tregs from ectopic ovarian lesions compared with paired eutopic endometria. PMEPA1 expression was increased in the ectopic lesions and peritoneal fluid mononuclear cells of patients with EMs. Tregs overexpressing PMEPA1 demonstrated reduced secretion of IL-10 and TGF-β but exhibited hyperactivation of the PI3K/AKT signaling pathway. Treatment with LY294002 ameliorated the impairment in cytokine secretion. Coculture experiments with Tregs expressing high levels of PMEPA1 resulted in increased invasion, migration, and proliferation of ESCs.
conclusionPMEPA1 impairs Treg-mediated immunosuppression by hyperactivating the PI3K/AKT pathway, thereby facilitating the invasiveness of ESCs in EMs.
Indexed as
Identifiers
41100035What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.